低级别胶质瘤对比增强与T2/FLAIR错配征的影像学评估:与分子分型的相关性
研究纳入三个独立数据库共316例低级别胶质瘤患者(151例II级、165例III级),分析术前MRI对比增强与T2-FLAIR错配征同分子分型的关系。结果显示对比增强在IDH野生型GBM样组最常见,T2-FLAIR错配征多见于IDH突变型星形细胞瘤组,且错配征在控制分子分型后与生存无关。
要点
- 对比增强肿瘤在IDH野生型GBM样组占57%,高于IDH突变型星形细胞瘤组的28%和IDH突变型少突胶质细胞瘤组的25.3%。
- T2-FLAIR错配征在IDH突变型星形细胞瘤组占73.1%(60/82),但控制分子分型后与生存无关。
- 年龄小于40岁、肿瘤大于6cm和T2-FLAIR错配征三者组合对IDH突变型星形细胞瘤具有高度特异性。
核心结论
- 研究识别出低级别胶质瘤分子分型的影像学相关特征,这些特征与临床人口学特征共同界定肿瘤的典型表现。
- 低级别胶质瘤的预后影像学相关因素需要在分子分型组内重新评估。
研究设计与样本
- 联合队列研究,从三个独立数据库识别316例低级别胶质瘤患者(151例II级和165例III级)。
- 分析术前轴位FLAIR、轴位T2加权和钆增强后容积T1加权MR图像。
- 收集IDH1/2、TP53、TERT启动子和ATRX突变状态以及1p/19q共缺失的分子数据。
- 在133例子集中评估T2-FLAIR错配征。
主要发现
- 胶质瘤分为三组:O组(IDH突变、1p/19q共缺失少突胶质细胞瘤,n=95)、A组(IDH突变、ATRX失活星形细胞瘤,n=175)和G组(IDH野生型、GBM样,n=46)。
- 对比增强肿瘤见于98例(31%),G组最常见(28/45,57%),高于A组(49/175,28%)和O组(24/95,25.3%)(分别p=0.008和p=0.0011)。
- T2-FLAIR错配征优先见于A组肿瘤(73.1%,60/82),但控制分子分型后其存在与生存无关。
- 假阳性错配征见于28.5%(12/42)的O组肿瘤,G组肿瘤中未见。
- 首次诊断时年龄小于40岁、肿瘤大小大于6cm和T2-FLAIR错配征三者组合对IDH突变型星形细胞瘤(A组)具有高度特异性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: With the updated World Health Organization (WHO) 2016 neuropathological diagnostic criteria, radiographic prognostic associations in lower-grade gliomas (LGG, WHO grade II and III) are undergoing re-evaluation. METHODS: We identified 316 LGG patients (151 grade II and 165 grade III) for a combined cohort from three independent databases. We analyzed the preoperative axial FLAIR, axial T2-weighted and post-gadolinium volumetric T1-weighted MR images. The molecular data collected included the status of IDH1/2, TP53, TERT promoter and ATRX mutations, in addition to 1p/19q co-deletions. In a subset of cases (n = 133), we assessed the "T2-FLAIR mismatch" sign. RESULTS: Gliomas were assigned to one of the three molecular groups: Group O (IDH-mutant, 1p/19q co-deleted oligodendrogliomas, n = 95), Group A (IDH-mutant, ATRX inactivated astrocytomas, n = 175) and Group G (IDH wild-type, GBM-like, n = 46). A contrast-enhancing tumor was seen in 98 patients (31%), most frequently in Group G (n = 28/45, 57%), when compared to Group A (n = 49/175, 28%) and Group O (n = 24/95, 25.3%) tumors (p = 0.008 and p = 0.0011, respectively). Consistent with previous reports, T2-FLAIR mismatch was preferentially found in Group A tumors (73.1%, 60 of 82), although its presence was not associated with survival, after controlling for molecular group. False positive mismatch sign was noted in 28.5% (12/42) Group O tumors, but none of the tumors in Group G. A combination of all three factors: age under 40 years at first diagnosis, a tumor size larger than 6 cm and T2-FLAIR mismatch was highly specific for IDH mutant astrocytoma (Group A). CONCLUSION: We identify radiographic correlates of molecular groups in lower-grade gliomas, which join clinical demographic features in defining the characteristic presentation of these tumors. Radiographic correlates of prognosis in LGG require re-evaluation within molecular group.
引用
- Juratli TA, Tummala SS, Riedl A, et al. Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. J Neurooncol. 2018. PMID: 30536195. doi:10.1007/s11060-018-03034-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。